ClinicalTrials.gg
Active, not recruitingNCT06786338Updated Sep 4, 2026

A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases

A Phase 2 interventional study of SGB-9768 in IgA Nephropathy (IgAN), C3 Glomerulopathy and IC-MPGN, sponsored by Suzhou Sanegene Bio Inc.. Active, not recruiting at 11 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Suzhou Sanegene Bio Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Glomerulonephritis, IGA with a site in China — 58 open to participants now, 73 under way, 20 of them phase 3. Glomerulonephritis, IGA · China.

Enrollment
69th of 109
45 · median 84
Started
2025
with 19 others
Phase 2
27 of 127
14 open now
Primary completion
2026-12
later than 19 of 72 live
Registered
80th of 127
by date

Among the 127 studies in Glomerulonephritis, IGA with a site in China, this one is the 69th largest by enrollment of the 109 interventional ones that give a count, is one of 20 that started in 2025, is one of 27 in phase 2, reaches primary completion later than 19 of the 72 other live ones, and was the 80th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

58 of the 127 studies in Glomerulonephritis, IGA with a site in China are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Glomerulonephritis, IGA with a site in China, or all of them as a file.
02

Study summary

This study looks at how well and safely SGB-9768 works for patients with certain kidney diseases: primary IgA nephropathy, C3 glomerulopathy, and immune complex-related membranoproliferative glomerulonephritis. It's a phase 2 trial done at several locations where both patients and doctors know what treatment is being given.

Read the detailed description

This is a phase 2, multicenter, open-label study to evaluate of the efficacy and safety of SGB-9768 in patients with primary IgA nephropathy, C3 glomerulopathy, and immune complex-mediated membranoproliferative glomerulonephritis. The primary objective is to evaluate efficacy of SGB-9768 in reducing urine protein excretion and maintain kidney function in these patients. Secondly, safety, pharmacokinetics and pharmacodynamics will be charaterized.

03

Conditions studied

  • IgA Nephropathy (IgAN)
  • C3 Glomerulopathy
  • IC-MPGN
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years
  • Weight ≥40 kg, with a (BMI) between 15 and 35 kg/m²
  • -confirmed diagnosis of primary IgA nephropathy, C3 glomerulopathy or IC-MPGN, accompanied by C3 deposition in the glomeruli.
  • Urine protein-to-creatinine ratio (UPCR) ≥0.75 g/g
  • Estimated (eGFR) (calculated using the CKD-EPI formula) must be ≥30 mL/min/1.73 m².
  • Must be on a stable maximum tolerated doses of ACE inhibitors (ACEI) or angiotensin receptor blockers (ARB) for at least 12 weeks
  • Participants of must use highly effective during the study and for at least 12 weeks following the end of the study or last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • Kidney indicates more than 50% tubular atrophy or interstitial fibrosis.
  • Kidney biopsy shows more than 50% formation of glomerular crescents, or clinical signs suggestive of rapidly progressive glomerulonephritis.
  • IgA nephropathy, C3 glomerulopathy, or IC-MPGN secondary to other diseases
  • Presence of other systemic diseases or kidney diseases that may cause proteinuria
  • Received or other immunomodulators within 90 days prior to the first administration of the drug
  • Received B-cell targeted biologics or other biologics within 180 days prior to the first administration of the investigational drug
  • Used SGLT2 inhibitors or endothelin receptor antagonists, unless have been stably used for 12 weeks or more
  • Significant comorbidities
  • History of any malignant tumors of any organ system within the past 5 years
  • History of severe trauma or major surgery within 12 weeks prior to screening, or plans to undergo surgery during the study.
  • History of immunodeficiency diseases, congenital asplenia or splenectomy.
  • History of recurrent invasive infections, active systemic bacterial, viral, or fungal infections
  • Positive test results for , ,
  • (ALT) or aspartate aminotransferase (AST) levels > 2.5 times the (ULN)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    IgAN-1

    2 doses of SGB-9768 by subcutaneous (sc) injection

    Drug: SGB-9768

  • Experimental
    IgAN-2

    2 doses of SGB-9768 by subcutaneous (sc) injection

    Drug: SGB-9768

  • Experimental
    C3G/IC-MPGN

    2 doses of SGB-9768 by subcutaneous (sc) injection

    Drug: SGB-9768

Interventions

  • SGB-9768 for subcutaneous (SC) injection

06

What researchers measure

Primary outcomes

  1. change from baseline in urine protein-creatinine ratio (UPCR)

    Time frame: 24 weeks

Secondary outcomes

  1. change from baseline in UACR and 24h-urine protein

    Time frame: 24 weeks

  2. change from baseline in estimated glomerular filtration rate (eGFR)

    Time frame: 36 weeks

  3. Number of Participants with Adverse Events (AEs) and/or Serious Adverse Events (SAEs)

    Time frame: from erollment through week 36

  4. Pharmacokinetics-Cmax

    Maximum Observed Plasma Concentration (Cmax)

    Time frame: 24 hours

  5. Pharmacokinetics-Tmax

    Time at which the maximum plasma concentration (Cmax) occurs

    Time frame: 24 hours

  6. Pharmacokinetics-AUClast

    Area under the plasma concentration-time curve from dosing (time zero) to the time of the last measured concentration

    Time frame: 24 hours

  7. Pharmacokinetics-t1/2

    Terminal Elimination Half-Life (t1/2)

    Time frame: 24 hours

  8. Pharmacodynamics-C3

    Change From Baseline in serum Complement 3 (C3) level

    Time frame: baseline through week 36

  9. Pharmacodynamics-complement classical pathway activity by Wieslab® CP

    Change From Baseline in serum Complement Classical Pathway Activity

    Time frame: baseline through week 36

  10. Pharmacodynamics-complement alternative pathway activity by Wieslab® AP

    Change From Baseline in Serum Complement Alternative Pathway Activity

    Time frame: baseline through week 36

07

Study locations

11 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2025
First posted
Jan 22, 2025
StartActual
Jun 6, 2025
Primary completionEst.
Dec 29, 2026
CompletionEst.
Dec 31, 2027
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06786338
Lead sponsor
Suzhou Sanegene Bio Inc.
Responsible party
Sponsor
First posted
Jan 22, 2025
Start date
Jun 6, 2025
Primary completion
Dec 29, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SGB-9768

Start the discussion